|
Sepracor was founded in 1984 by its Executive Chairman, Timothy Barberich. Mr. Barberich served as President and Chief Executive Officer from 1984 through 1999, at which time Mr. Barberich was elected Chairman of the Board of Directors, and in May 2007, Mr. Barberich transitioned from Chairman and CEO and became Executive Chairman.
Under Mr. Barberich's leadership, Sepracor became a publicly traded company in 1991 and spun off four publicly traded companies: Chirex (which, through a series of acquisitions, was ultimately acquired by Rhodia in 2000); HemaSure, which merged with Point Therapeutics (OTC BB: POTP.OB); BioSepra, now known as BioSphere Medical (Nasdaq: BSMD); and Versicor, which became known as Vicuron Pharmaceuticals and which was subsequently acquired by Pfizer.
Prior to founding Sepracor, Mr. Barberich spent 10 years at Millipore Corporation, a Bedford, Massachusetts-based company that provides leading separations products to diversified market segments including the life science research, pharmaceutical, biotechnology and electronic markets. While at Millipore, he held a variety of marketing, sales, and general management positions. Prior to Millipore, Mr. Barberich held project management and research scientist positions at American Cyanamid Company.
Mr. Barberich serves as Executive Chairman, and as a board member of BioSphere Medical, Point Therapeutics, and Gemin X.
| 